323.58MMarket Cap-4.54P/E (TTM)
22.199High20.995Low212.53KVolume21.120Open21.530Pre Close4.59MTurnover2.12%Turnover RatioLossP/E (Static)15.00MShares31.01052wk High3.87P/B216.50MFloat Cap5.02052wk Low--Dividend TTM10.04MShs Float188.800Historical High--Div YieldTTM5.59%Amplitude3.862Historical Low21.598Avg Price1Lot Size
Jasper Therapeutics Stock Forum
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet